1. Hollenberg NK, Chenitz WR, Adams DF, Williams GH 1974 Reciprocal influence of salt intake on adrenal glomerulosa and renal vascular responses to angiotensin II in normal man. JCI 54:34-42.

2. Williams GH HN 1985 Sodium sensitive essential hypertension emerging insights into pathogenesis and therapeutic implications. In: Klahr S MS (ed) Contemporary Nephrology, 3rd ed. Plenum, New York, pp 303-331

3. Williams GH DR 1998 Diseases of the adrenal cortex. In: Fauci AS BE, Isselbacher KJ, et al (ed) Harrison's Principles of Internal Medicine, 14th ed. McGraw-Hill, New York, pp 1380-1394

4. Tanabe A, Naruse M, Naruse K, et al. 1997 Left ventricular hypertrophy is more prominent in patients with primary aldosteronism than in patients with other types of secondary hypertension. Hypertens Res 20:85-90.

5. Young M, Fullerton M, Dilley R, Funder J 1994 Mineralocorticoids, hypertension, and cardiac fibrosis. JCI 93:2578-83.

6. Rocha R, Chander PN, Zuckerman A, Stier CT, Jr. 1999 Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats. hyper 33:232-7.

7. Brilla CG, Matsubara LS, Weber KT 1993 Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension. Am J Cardiol 71:12A-16A.

8. Pitt B, Zannad F, Remme WJ, et al. 1999 The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. NEJM 341:709-17

9. Pitt B, Remme W, Zannad F, et al. 2003 Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. NEJM 348:1309-21

10. Anderson GH, Jr., Blakeman N, Streeten DH 1994 The effect of age on prevalence of secondary forms of hypertension in 4429 consecutively referred patients. J Hypertens 12:609-15.

11. Gordon RD 1994 Mineralocorticoid hypertension. Lancet 344:240-3.

12. Hiramatsu K, Yamada T, Yukimura Y, et al. 1981 A screening test to identify aldosterone-producing adenoma by measuring plasma renin activity. Results in hypertensive patients. Arch Intern Med 141:1589-93.

13. Young WF, Jr., Hogan MJ, Klee GG, Grant CS, van Heerden JA 1990 Primary aldosteronism: diagnosis and treatment. Mayo Clin Proc 65:96-110.

14. Lim PO, Rodgers P, Cardale K, Watson AD, MacDonald TM 1999 Potentially high prevalence of primary aldosteronism in a primary-care population. Lancet 353:40.

15. Mulatero P, Stowasser M, Loh KC, et al. 2004 Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab 89:1045-50

16. Albers FJ 1994 Clinical characteristics of atherosclerotic renovascular disease. Am J Kidney Dis 24:636-41.

17. Kono T, Ikeda F, Oseko F, Imura H, Tanimura H 1981 Normotensive primary aldosteronism: report of a case. J Clin Endocrinol Metab 52:1009-13.

18. Litchfield WR, Dluhy RG 1995 Primary aldosteronism. Endocrinol Metab Clin North Am 24:593-612.

19. Kaplan NM 2004 The current epidemic of primary aldosteronism: causes and consequences. J Hypertens 22:863-9

20. Stewart PM 1999 Mineralocorticoid hypertension. Lancet 353:1341-7

21. Li JT, Shu SG, Chi CS 1994 Aldosterone-secreting adrenal cortical adenoma in an 11-year-old child and collective review of the literature. Eur J Pediatr 153:715-7.

22. Melby JC 1984 Primary aldosteronism. Kidney Int 26:769-78.

23. Gordon RD, Klemm SA, Tunny TJ, Stowasser M 1992 Primary aldosteronism: hypertension with a genetic basis. Lancet 340:159-61.

24. Gordon RD SM, Klemm SA, Tunny TJ 1994 Primary aldosteronism and other forms of mineralocorticoid hypertension. In: J S (ed) Textbook of hypertension. Blackwell Scientific, Oxford, pp 865-92

25. Wisgerhof M, Brown RD, Hogan MJ, Carpenter PC, Edis AJ 1981 The plasma aldosterone response to angiotensin II infusion in aldosterone-producing adenoma and idiopathic hyperaldosteronism. J Clin Endocrinol Metab 52:195-8.

26. Sheaves R, Goldin J, Reznek RH, et al. 1996 Relative value of computed tomography scanning and venous sampling in establishing the cause of primary hyperaldosteronism. Eur J Endocrinol 134:308-13.

27. Biglieri EG, Kater CE 1991 Steroid characteristics of mineralocorticoid adrenocortical hypertension. Clin Chem 37:1843-8.

28. Gordon RD 1995 Primary aldosteronism. JEI 18:495-511.

29. Lifton RP, Dluhy RG, Powers M, et al. 1992 A chimaeric 11 beta-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature 355:262-5.

30. Dluhy RG, Lifton RP 1994 Glucocorticoid-remediable aldosteronism. Endocrinol Metab Clin North Am 23:285-97.

31. Dluhy RG, Lifton RP 1999 Glucocorticoid-remediable aldosteronism. J Clin Endocrinol Metab 84:4341-4

32. Quinkler M, Stewart PM 2003 Hypertension and the cortisol-cortisone shuttle. J Clin Endocrinol Metab 88:2384-92

33. New MI 2002 Hypertension in congenital adrenal hyperplasia and apparent mineralocorticoid excess. Ann N Y Acad Sci 970:145-54

34. Conn JW, Cohen EL, Lucas CP, et al. 1972 Primary reninism. Hypertension, hyperreninemia, and secondary aldosteronism due to renin-producing juxtaglomerular cell tumors. Arch Intern Med 130:682-96.

35. Thompson GB, Young WF, Jr. 2003 Adrenal incidentaloma. Curr Opin Oncol 15:84-90

36. Weinberger MH, Fineberg NS 1993 The diagnosis of primary aldosteronism and separation of two major subtypes. Arch Intern Med 153:2125-9.

37. Blumenfeld JD, Sealey JE, Schlussel Y, et al. 1994 Diagnosis and treatment of primary hyperaldosteronism. Ann Intern Med 121:877-85.

38. Montori VM, Young WF, Jr. 2002 Use of plasma aldosterone concentration-to-plasma renin activity ratio as a screening test for primary aldosteronism. A systematic review of the literature. Endocrinol Metab Clin North Am 31:619-32, xi

39. Young WF, Jr., Stanson AW, Grant CS, Thompson GB, van Heerden JA 1996 Primary aldosteronism: adrenal venous sampling. Surgery 120:913-9; discussion 919-20.

40. Magill SB, Raff H, Shaker JL, et al. 2001 Comparison of adrenal vein sampling and computed tomography in the differentiation of primary aldosteronism. J Clin Endocrinol Metab 86:1066-71

41. Dunnick NR, Leight GS, Jr., Roubidoux MA, Leder RA, Paulson E, Kurylo L 1993 CT in the diagnosis of primary aldosteronism: sensitivity in 29 patients. AJR Am J Roentgenol 160:321-4.

42. Sfakianakis GN, Bourgoignie JJ, Georgiou M, Guerra JJ, Jr. 1993 Diagnosis of renovascular hypertension with ACE inhibition scintigraphy. Radiol Clin North Am 31:831-48.

43. Sawka AM, Young WF, Thompson GB, et al. 2001 Primary aldosteronism: factors associated with normalization of blood pressure after surgery. Ann Intern Med 135:258-61

44. Kendrick ML, Curlee K, Lloyd R, et al. 2002 Aldosterone-secreting adrenocortical carcinomas are associated with unique operative risks and outcomes. Surgery 132:1008-11; discussion 1012

45. Ghose RP, Hall PM, Bravo EL 1999 Medical management of aldosterone-producing adenomas. Ann Intern Med 131:105-8

46. Hsueth W 1986 New Insights into the medical management of primary aldosteronism. hyper 8:76-82

47. Lim PO, Young WF, MacDonald TM 2001 A review of the medical treatment of primary aldosteronism. J Hypertens 19:353-61

48. Griffing GT, Cole AG, Aurecchia SA, Sindler BH, Komanicky P, Melby JC 1982 Amiloride in primary hyperaldosteronism. Clin Pharmacol Ther 31:56-61.